ArticleNanomaterials (Basel, Switzerland)2018
A Method for Efficient Loading of Ciprofloxacin Hydrochloride in Cationic Solid Lipid Nanoparticles: Formulation and Microbiological Evaluation.
Article in Nanomaterials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Systematic Study of Ciprofloxacin Release from Lipid-Based Nanocarriers.Pharmaceutics · 2026Article
- Development and optimization of Moxifloxacin solid lipid nanoparticles via double emulsion organic solvent free technique applying Box-Behnken experimental design.Scientific reports · 2025Article
- Nano-encapsulated Melissa officinalis Essential Oil and Its Antibacterial Effects Against Multi Drug Resistant E. coli and K. pneumonia.Current microbiology · 2025Article
- Development of Poly(vinyl alcohol)-Chitosan Composite Nanofibers for Dual Drug Therapy of Wounds.ACS omega · 2024Article
- Antibiotics-encapsulated nanoparticles as an antimicrobial agent in the treatment of wound infection.Frontiers in immunology · 2024Article
- Emphasis on Nanostructured Lipid Carriers in the Ocular Delivery of Antibiotics.Pharmaceutical nanotechnology · 2024Review
- Synthesis and Characterization of Antibacterial Chitosan Films with Ciprofloxacin in Acidic Conditions.International journal of molecular sciences · 2023Article
- Nanoparticular and other carriers to deliver lactoferrin for antimicrobial, antibiofilm and bone-regenerating effects: a review.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Review
- Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives.Drug delivery · 2022Review
- Development of Ciprofloxacin-Loaded Bilosomes In-Situ Gel for Ocular Delivery: Optimization, In-Vitro Characterization, Ex-Vivo Permeation, and Antimicrobial Study.Gels (Basel, Switzerland) · 2022Article
- Development and Optimization of Ciprofloxacin HCl-Loaded Chitosan Nanoparticles Using Box-Behnken Experimental Design.Molecules (Basel, Switzerland) · 2022Article
- Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.Pharmaceutics · 2022Article
- Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field.Pharmaceutics · 2022Review
- Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems.Molecules (Basel, Switzerland) · 2022Review
- Different Nanotechnology Approaches for Ciprofloxacin Delivery Against Multidrug-Resistant Microbes.Infection and drug resistance · 2022Review
- Composites Based on Gellan Gum, Alginate and Nisin-Enriched Lipid Nanoparticles for the Treatment of Infected Wounds.International journal of molecular sciences · 2021Article
- Incorporation of Antibiotics into Solid Lipid Nanoparticles: A Promising Approach to Reduce Antibiotic Resistance Emergence.Nanomaterials (Basel, Switzerland) · 2021Review
- Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation.Pharmaceutics · 2021Review
- Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.International journal of nanomedicine · 2021Article
- Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was the production of solid lipid nanoparticles (SLN) loaded with ciprofloxacin (CIP) through two different production techniques, quasi-emulsion solvent diffusion (QESD) and solvent injection (SI). In order to efficaciously entrap the commercial salt form (hydrochloride) of the antibiotic in these lipid systems, a conversion of CIP hydrochloride to the free base was realized in situ, through the addition of triethylamine. To ensure physical stability to the carriers over time and ameliorate the interaction with bacterial cell membranes, positively charged SLN were produced by addition of the cationic lipid didecyldimethylammonium bromide (DDAB). Homogeneous SLN populations with a mean particle sizes of 250⁻350 nm were produced by both methods; drug encapsulation was over 85% for most samples. The SLN were physically stable for up to nine months both at 4 °C and 25 °C, although the former condition appears more suitable to guarantee the maintenance of the initial particle size distribution. As expected, CIP encapsulation efficiency underwent a slight reduction after nine months of storage, although the initial high drug content values would ensure a residual concentration of the antibiotic in the SLN still appropriate to exert an acceptable antibacterial activity. Selected SLN formulations were subjected to an in vitro microbiological assay against different bacterial strains, to verify the effect of nanoencapsulation on the cell growth inhibitory activity of CIP. In general, CIP-SLN produced without DDAB showed MIC values for CIP comparable to those of the free drug. Conversely, addition of increasing percentages of the cationic lipid, reflected by a progressive increase of the positive value of the Zeta potential, showed a variety of MIC values against the various bacterial strains, but with values 2⁻4 order of dilution lower than free CIP. An hypothesis of the effect of the cationic lipid upon the increased antibacterial activity of CIP in the nanocarriers is also formulated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.